ArticleCell death and differentiation2025
MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.
Article in Cell death and differentiation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- An immuno-chemotherapeutic bone scaffold for tumor eradication and bone regeneration in drug-resistant osteosarcoma.Bioactive materials · 2026Article
- Review
- Direct peroxisome-mitochondria contact modulates ROS under stress.Science China. Life sciences · 2026Article
- Bidirectional regulation of the ubiquitin-RNA modification axis in cancer.Frontiers in oncology · 2026Review
- YBX1 as an adaptive RNA hub in cancer: linking state-dependent RNA regulation to tumor immunity, metabolic reprogramming, and therapy resistance.Frontiers in immunology · 2026Review
- The effect of postoperative chemotherapy on survival outcomes and a nomogram for predicting overall survival in chondroblastic osteosarcoma.Scientific reports · 2025Article
- Multifaceted functions of Y‑box binding protein 1 in RNA methylated modifications (Review).Molecular medicine reports · 2025Review
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
- Intelligent Nanomedicine Systems Utilizing Diverse Nanoparticles for Osteosarcoma Therapy: A Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common primary malignant bone tumor in children and adolescents and is often characterized by resistance to chemotherapy. Although RNA 5‑methylcytosine (m5C) modification is known to contribute to tumor progression, its exact role in osteosarcoma drug resistance remains poorly understood. Here, we identify NOP2/Sun RNA methyltransferase family member 6 (NSUN6) as an m5C methyltransferase that positively correlates with osteosarcoma progression. Mechanistically, the E3 ubiquitin ligase membrane‑associated RING‑CH‑type finger 8 (MARCH8) ubiquitinates NSUN6 at Lys271 and Lys462, leading to its proteasomal degradation. Reduced NSUN6 expression lowers m5C modification on peroxisomal biogenesis factor 1 (PEX1) and peroxisomal biogenesis factor 3 (PEX3) mRNAs, destabilizing them through loss of binding by the m5C reader YBX1. In turn, this downregulates peroxisome synthesis and catalase (CAT) protein production, causing increased intracellular reactive oxygen species (ROS), DNA damage, and heightened sensitivity of osteosarcoma cells to cisplatin. Furthermore, elevated ROS levels reinforce NSUN6 ubiquitination and degradation by enhancing the NSUN6-MARCH8 interaction, establishing a positive feedback loop. Collectively, these findings highlight an intricate NSUN6-m5C-YBX1-PEXs signaling axis that governs peroxisome biogenesis, ROS accumulation, and cisplatin responsiveness in osteosarcoma. Our work not only clarifies the role of m5C in osteosarcoma drug resistance but also offers a potential therapeutic angle for targeting NSUN6 and its peroxisome‑regulating network to overcome chemoresistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.